A research group from the Graduate School of Medicine and Research Institute of Environmental Medicine at Nagoya University report that cholesterol accumulation in macrophages promotes liver fibrosis in the development of non-alcoholic steatohepatitis (NASH).
To further understand the mechanism, the group led by Nagoya University doctors Takayoshi Suganami and Michiko Itoh used a combination of techniques to identifyin the lipids of the dead hepatocytes and the macrophages that engulf the cells.
When they administered the supramolecule to mice, they found that it accumulated in the liver where it promoted excretion of cholesterol, which effectively stopped the progression of NASH.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stem cell therapy shows promise in treating COVID-19 complicationsThe use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
Read more »
Updated guidance on treating COVID-19 patients in outpatient settingsIn an updated rapid, living practice points, the American College of Physicians (ACP) summarizes the latest evidence on the use of pharmacologic and biologic treatments of COVID-19 in the outpatient setting, specifically addressing the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant. The paper is published in Annals of Internal Medicine.
Read more »
Team discovers markers that can predict how children will tolerate sweetened medicineAlthough there are some cultural exceptions to the rule, medicines for children are often given in liquid form that is sweetened to make it taste good. But not every child experiences the same medicine in the same way.
Read more »
Nuclear medicine treatment cures lethal form of ovarian cancer in preclinical settingA new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the Journal of Nuclear Medicine.
Read more »
Belfast business owner to relocate shop after fourth attack in two weeksPolice are treating it as a 'race-motivated hate crime'
Read more »
Dad of ill daughter shares how lives have plunged into a nightmareSpecialists told a judge that Indi could not be helped by 'the best of modern medicine'
Read more »